SG11201906958TA - Aryl hydrocarbon receptor (ahr) modulator compounds - Google Patents
Aryl hydrocarbon receptor (ahr) modulator compoundsInfo
- Publication number
- SG11201906958TA SG11201906958TA SG11201906958TA SG11201906958TA SG11201906958TA SG 11201906958T A SG11201906958T A SG 11201906958TA SG 11201906958T A SG11201906958T A SG 11201906958TA SG 11201906958T A SG11201906958T A SG 11201906958TA SG 11201906958T A SG11201906958T A SG 11201906958TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ahr
- compounds
- aryl hydrocarbon
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIP0 I PCT omit IIl °nolo DID mil OH im voila° oimIE (10) International Publication Number WO 2018/141857 Al (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, CO7D 471/04 (2006.01) A61P 35/00 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61K 31/437 (2006.01) (21) International Application Number: (22) International Filing Date: PCT/EP2018/052542 Published: — with international search report (Art. 21(3)) 01 February 2018 (01.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17000158.0 01 February 2017 (01.02.2017) EP (71) Applicant: PHENEX PHARMACEUTICALS AG [DE/DE]; Donnersbergweg 1, 67059 Ludwigshafen (DE). (72) Inventors: STEENECK, Christoph; Weberstrasse 4/2, 69120 Heidelberg (DE). DEUSCHLE, Ulrich; Maulbeer- stiick 11, 67346 Speyer (DE). ALBERS, Michael; Sch- wabenstr. 6 A, 68239 Mannheim (DE). HOFFMANN, Thomas; Daimlerstrasse 21, 67346 Speyer (DE). (74) Agent: GOLDBACH, Klara; Griinecker Patent- and Rechtsanwalte PartG mbB, Leopoldstr. 4, 80802 Munich (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 1-1 (54) Title: ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS IN kin (57) : The present invention relates to compounds which can act as aryl hydrocarbon GP R 2 receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates 1-1 R3 to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions 71' --.... 0 through binding of said aryl hydrocarbon receptor by said compounds. ri N A B 1-1 1-1 I N Rb Rb (I) C
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17000158 | 2017-02-01 | ||
PCT/EP2018/052542 WO2018141857A1 (en) | 2017-02-01 | 2018-02-01 | Aryl hydrocarbon receptor (ahr) modulator compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906958TA true SG11201906958TA (en) | 2019-08-27 |
Family
ID=57960223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906958TA SG11201906958TA (en) | 2017-02-01 | 2018-02-01 | Aryl hydrocarbon receptor (ahr) modulator compounds |
Country Status (28)
Country | Link |
---|---|
US (1) | US10981908B2 (en) |
EP (1) | EP3577112B1 (en) |
JP (1) | JP6849823B2 (en) |
KR (1) | KR102320516B1 (en) |
CN (1) | CN110248940B (en) |
AR (1) | AR110789A1 (en) |
AU (1) | AU2018216957B2 (en) |
BR (1) | BR112019015716A2 (en) |
CA (1) | CA3050827C (en) |
CL (1) | CL2019002108A1 (en) |
CO (1) | CO2019007881A2 (en) |
CR (1) | CR20190392A (en) |
CU (1) | CU20190069A7 (en) |
EA (1) | EA038318B1 (en) |
EC (1) | ECSP19055169A (en) |
ES (1) | ES2858329T3 (en) |
IL (1) | IL268080B (en) |
MX (1) | MX2019008994A (en) |
MY (1) | MY196831A (en) |
NI (1) | NI201900076A (en) |
PE (1) | PE20191478A1 (en) |
PH (1) | PH12019550135A1 (en) |
SG (1) | SG11201906958TA (en) |
TW (1) | TWI752155B (en) |
UA (1) | UA122745C2 (en) |
UY (1) | UY37589A (en) |
WO (1) | WO2018141857A1 (en) |
ZA (1) | ZA201904771B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI752155B (en) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | ARYL HYDROCARBON RECEPTOR (AhR) MODULATOR COMPOUNDS |
TWI674260B (en) * | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | Aryl hydrocarbon receptor (ahr) modulator compounds |
DK3749669T3 (en) | 2018-02-06 | 2023-06-06 | Ideaya Biosciences Inc | AHR MODULATORS |
WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
KR20210111762A (en) * | 2018-11-30 | 2021-09-13 | 셀룰래리티 인코포레이티드 | Proliferation of Natural Killer Cells and ILC3 Cells Using Novel Aromatic Compounds |
US20230108408A1 (en) * | 2020-01-23 | 2023-04-06 | Phenex Pharmaceuticals Ag | Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
US20230279000A1 (en) | 2020-02-26 | 2023-09-07 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of ahr signalling |
WO2021242955A1 (en) * | 2020-05-28 | 2021-12-02 | Senda Biosciences, Inc. | Fused azole heterocycles as ahr antagonists |
CN114181212B (en) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | Pyridazinone AhR inhibitors |
CN114835687B (en) * | 2021-04-02 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR inhibitors |
WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992002500A1 (en) | 1990-07-31 | 1992-02-20 | Teikoku Hormone Mfg. Co., Ltd. | 2-phenylindole derivative |
ES2215242T3 (en) * | 1996-11-19 | 2004-10-01 | Amgen Inc. | ANTI-INFLAMMATORY AGENTS OF CONDENSED PIRROL REPLACED WITH ARILO AND HETEROARILO. |
AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
JP2009515926A (en) | 2005-11-18 | 2009-04-16 | エフ.ホフマン−ラ ロシュ アーゲー | Azaindole-2-carboxamide derivatives |
US8563573B2 (en) * | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
CA2777565C (en) | 2009-10-13 | 2019-06-18 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic diphenylamine small molecule compounds and their uses |
CN102573470A (en) | 2009-11-02 | 2012-07-11 | 宋嘉盛 | ITE for cancer intervention and eradication |
US20130338201A1 (en) * | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
PT2531501E (en) | 2010-02-03 | 2014-02-17 | Takeda Pharmaceutical | Apoptosis signal-regulating kinase 1 inhibitors |
US8410117B2 (en) * | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
TWI510487B (en) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2012015914A2 (en) | 2010-07-27 | 2012-02-02 | Trustees Of Boston University | Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
CN104755461A (en) | 2012-10-17 | 2015-07-01 | 霍夫曼-拉罗奇有限公司 | 6-aminoindole derivatives as TRP channel antagonists |
SG10201707095QA (en) | 2012-12-21 | 2017-09-28 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
TWI752155B (en) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | ARYL HYDROCARBON RECEPTOR (AhR) MODULATOR COMPOUNDS |
TWI674260B (en) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | Aryl hydrocarbon receptor (ahr) modulator compounds |
TW201835070A (en) | 2017-02-21 | 2018-10-01 | 德商菲尼克斯製藥股份有限公司 | ARYL HYDROCARBON RECEPTOR (AhR) MODULATOR COMPOUNDS |
-
2018
- 2018-01-26 TW TW107102803A patent/TWI752155B/en active
- 2018-01-31 UY UY0001037589A patent/UY37589A/en not_active Application Discontinuation
- 2018-01-31 AR ARP180100227A patent/AR110789A1/en unknown
- 2018-02-01 KR KR1020197023990A patent/KR102320516B1/en active IP Right Grant
- 2018-02-01 AU AU2018216957A patent/AU2018216957B2/en active Active
- 2018-02-01 CR CR20190392A patent/CR20190392A/en unknown
- 2018-02-01 US US16/479,130 patent/US10981908B2/en active Active
- 2018-02-01 MY MYPI2019004031A patent/MY196831A/en unknown
- 2018-02-01 JP JP2019561370A patent/JP6849823B2/en active Active
- 2018-02-01 CA CA3050827A patent/CA3050827C/en active Active
- 2018-02-01 WO PCT/EP2018/052542 patent/WO2018141857A1/en unknown
- 2018-02-01 CU CU2019000069A patent/CU20190069A7/en unknown
- 2018-02-01 SG SG11201906958TA patent/SG11201906958TA/en unknown
- 2018-02-01 EA EA201991599A patent/EA038318B1/en unknown
- 2018-02-01 PE PE2019001482A patent/PE20191478A1/en unknown
- 2018-02-01 UA UAA201908353A patent/UA122745C2/en unknown
- 2018-02-01 MX MX2019008994A patent/MX2019008994A/en unknown
- 2018-02-01 ES ES18701774T patent/ES2858329T3/en active Active
- 2018-02-01 EP EP18701774.4A patent/EP3577112B1/en active Active
- 2018-02-01 BR BR112019015716-6A patent/BR112019015716A2/en not_active IP Right Cessation
- 2018-02-01 CN CN201880009354.9A patent/CN110248940B/en active Active
-
2019
- 2019-07-15 NI NI201900076A patent/NI201900076A/en unknown
- 2019-07-15 IL IL268080A patent/IL268080B/en unknown
- 2019-07-19 ZA ZA2019/04771A patent/ZA201904771B/en unknown
- 2019-07-23 CO CONC2019/0007881A patent/CO2019007881A2/en unknown
- 2019-07-24 PH PH12019550135A patent/PH12019550135A1/en unknown
- 2019-07-29 CL CL2019002108A patent/CL2019002108A1/en unknown
- 2019-07-31 EC ECSENADI201955169A patent/ECSP19055169A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
SG11201408261UA (en) | Syringe | |
SG11201407200TA (en) | Liquid formulation | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201804395PA (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
SG11201407961WA (en) | Risperidone or paliperidone implant formulation | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease | |
SG11201808686VA (en) | Synthesis of indazoles | |
SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
SG11201906767XA (en) | Estrogen receptor modulators | |
SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
SG11201901249YA (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
SG11201908513RA (en) | Peptides for treatment of diabetes | |
SG11201806424TA (en) | Therapeutic compounds |